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Abstract
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is implicated in certain types of
lymphoid and myeloid malignancies. However, the molecular mechanisms underlying its interactions with these
malignancies are largely unknown. In this study, we have first profiled molecular signatures associated with IRF4 expression
in associated cancers, by analyzing existing gene expression profiling datasets. Our results show that IRF4 is overexpressed
in melanoma, in addition to previously reported contexts including leukemia, myeloma, and lymphoma, and that IRF4 is
associated with a unique gene expression pattern in each context. A pool of important genes involved in B-cell
development, oncogenesis, cell cycle regulation, and cell death including BATF, LIMD1, CFLAR, PIM2, and CCND2 are
common signatures associated with IRF4 in non-Hodgkin B cell lymphomas. We confirmed the correlation of IRF4 with
LIMD1 and CFLAR in a panel of cell lines derived from lymphomas. Moreover, we profiled the IRF4 transcriptome in the
context of EBV latent infection, and confirmed several genes including IFI27, IFI44, GBP1, and ARHGAP18, as well as CFLAR
as novel targets for IRF4. These results provide valuable information for understanding the IRF4 regulatory network, and
improve our knowledge of the unique roles of IRF4 in different hematological malignancies.
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Introduction
IRF4 is a lymphocyte-specific transcription factor, and its
expression is confined to immune cells including B cells,
macrophages, and CD11b+ DCs. IRF4 can be induced by various
mitogenic stimuli which commonly activate NFkB for the
activation of the IRF4 gene promoter [1]. As a transcription
factor, IRF4 exerts its functions through regulation of its
transcriptional targets involved in cell development, immune
response, and oncogenesis. IRF4 is a quintessential ‘context-
dependent’ transcription factor, and regulates distinct groups of
targets in different contexts. Its DNA-binding specificity depends
on lineage-specific transcriptional co-regulators. Many of these co-
regulators have been identified, including two Ets family members
PU.1 and SPIB, BATF, DEF6, STAT3, NFAT, FKBP52 and
PGC-1a [2–12]. Ets and BATF are dominant co-regulators for
IRF4 in B and T lymphocytes, respectively [6,9,11,13]. When
interacting with one of the Ets family members, IRF4, like its
closest family member IRF8, binds to a composite Ets/ISRE-
consensus element (EICE) with the consensus sequence 59-
GGAANNGAAA-39, that fuses the Ets-binding motif (59-
GGAA-39) with the IRF-binding motif (59-AANNGAAA-39), or
to the Ets/IRF-responsive element (EIRE) with the consensus
sequence 59-GGAAANNGAAA-39, or to the IRF/Ets-consensus
sequence (IECS) 59-GAAANN(N)GGAA-39. When IRF4 interacts
with BATF that belongs to the AP1/ATF superfamily of
transcription factors, the complex IRF4-BATF binds to a
composite DNA element called AICE (TGANTCA/GAAA)
[14,15].
Increasing evidence has implicated IRF4 in hematological
malignancies. IRF4 overexpression is a hallmark of the activated
B-cell-like (ABC) type of diffuse large B-cell lymphoma (DLBCL)
and multiple myeloma (MM) [3,13], and is also overexpressed in
almost 100% cases of classical Hodgkin lymphoma (cHL), plasma
cell myeloma and primary effusion lymphoma (PEL) [16].
Interestingly, high levels of IRF4 protein exist in Epstein-Barr
virus (EBV)-transformed cells and associated B-cell lymphomas
with Type 3 latency [17–20], as well as in Human T-cell Leukemia
Virus-1 (HTLV1)-infected cell lines and associated Adult T-cell
Leukemia (ATL) [21–25]. Chromosomal translocation and genetic
mutation of IRF4 have been identified in MM, peripheral T-cell
lymphomas [26], and Chronic Lymphocytic Leukemia (CLL) [27].
In clinical practice, IRF4 serves as an important prognostic and
diagnostic marker for certain types of hematological malignancies
[28–30]. These lines of evidence highlight the importance of IRF4
in hematological malignancies. However, only very limited
transcriptional targets have been identified for IRF4 in these
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malignancies, and the role of IRF4 in tumorigenesis remains to be
elucidated.
In this study, we aim to profile IRF4-associated unique
molecular signatures in different types of hematological malignan-
cies, by analyzing existing gene expression profile databases
obtained from clinical samples. Results show that IRF4 is
overexpressed in melanoma, in addition to previously reported
myeoloma, lymphoma, and leukemia, and that IRF4 is associated
with a unique gene expression pattern in each of these settings.
Some of these genes are known IRF4 transcriptional targets,
whereas some others may represent a new group of IRF4 targets.
We have verified LIMD1 and CFLAR as two novel genes whose
expression is correlated with IRF4 in non-Hodgkin lymphomas,
and shown that CFLAR is likely an IRF4 target. Moreover, we
have profiled the IRF4 transcriptome in EBV latency by using
Microarray analysis and further confirmed a panel of genes
including IFI27, IFI44, GBP1, and ARHGAP18 as novel IRF4
targets.
Materials and Methods
Datasets and Oncomine Bioinformatics
All datasets selected for this study are available on Oncomine
website (www.oncomine.org). These datasets were log-trans-
formed, median centered per array, and standard deviation
normalized to one per array. Bioinformatic analysis was performed
at Oncomine website, with the default parameters on the site for
IRF4 co-expression analysis (threshold by p value: 1024, fold
change: 2, and gene rank: top 10%).
GEO Bioinformatics
Raw data from existing Gene Expression Omnibus (GEO)
datasets were downloaded. The intensity values were extracted
using GeneSpring GX 12.5 software from Agilent and scaled and
Quantile normalized. Values were then log transformed (base 2) to
the median of all samples on the R/Bioconductor package. Two
probes assigned to IRF4 gene, 204562_at and 216986_s_at, were
used to divide the samples into IRF4+ and IRF4– groups. Probe
216987_at was not used as it has small variance and low
expression value (mean value: 5.527 and variance 0.042).
Differentially expressed genes between the two groups (IRF4+
and IRF4–) were identified using limma R package from
Bioconductor with a simple two group design matrix (cut-off p#
0.05 and fold change $1.5). Limma is a popular library for
analysis of gene expression microarray data, it uses linear model to
accommodate complicated experimental design and Empirical
Bayesian to provide stable results for small datasets. Benjamin-
Hochberg was used for multiple testing correction.
Cell Lines
These cell lines used in this study are well established B cell lines
and have been worldwide used for EBV research for many years
[31–34]. Akata, Sav I, Sav III, JiJoye, and P3HR1 are Burkitt’s
lymphoma cell lines which were derived from patients. DG75 is an
EBV-negative B cell line. IB4 and LCL.Jul are lymphoblastic cell
lines in vitro transformed with EBV. All B cell lines are cultured in
RPMI1640 medium plus 10% FBS and antibiotics.
Plasmids, Reagents and Antibodies
The shIRF4 and retrovirus-mediated transfection and selection
of stable transfectants were described in our previous publication
[35]. Anti-LIMD1 clone H-4 (Santa Cruz), anti-FLIPs clone G-11
(Santa Cruz), anti-LMP1 CS1–4 (Dako), anti-IRF4 H140 (Santa
Cruz), and anti-GAPDH (Sigma) were used for Western blotting.
RNA Isolation, Microarray Analysis and Real-time PCR
Total RNAs from JiJoye and IB4 cell lines stably expressing
shIRF4 or control were isolated using RNeasy mini kit (Qiagen)
according to the manufacturer’s protocols. The eluted RNA was
subjected to reverse transcriptase reactions, which were performed
with the use of GoScript RT kit (Promega) following the
manufacturer’s instructions. cDNAs were subjected to MOgene
company (Saint Louis, MO) for Microarray analysis, with Agilent
HD 4644 k format (G4845F 026652) chips. A cross-labeling
duplicate, i.e. Cy5-labeled cDNA chip for shCtl/Cy3-labeled
cDNA chip for shIRF4 and Cy3-labeled chip for shCtl/Cy5-
labeled chip for shIRF4, were performed for each cell line. Genes
were selected with 2-fold changes as threshold.
Selected genes were confirmed by real-time PCR, as described
in our previous publication [35], with specific primers. IFI27
forward: 59-TGGCCAGGATTGCTACAGTTG-39, and reverse:
59-TATGGAGGACGAGGCGATTC-39, GBP1 forward: 59-
TGGAACGTGTGAAAGCTGAG-39, and reverse: 59-TGA-
CAGGAAGGCTCTGGTCT-39, IFI44 forward: 59- TAC-
CAGTTTAATCCCATGGAATCA-39, and reverse: 59- CAAA-
TACAAATGCCACACAATGAA-39, and ARHGAP18 forward:
59-AAGAGTACAAATGATGCTGACG-39 and reverse: 59-
CCTGGCAAGTACATCACTGG-39.
Results
IRF4 Expression Levels in Different Cancers
We initially checked the expression levels of IRF4 in different
cancer cell lines. To this end, the gene expression data, obtained
from 917 cell lines in a previous study [36], was analyzed at
Oncomine (http://www.oncomine.org). As shown in Fig. 1A, in
18 selected cancer types, the expression level of IRF4 was the
highest in myeloma, followed by lymphoma, melanoma and
leukemia. Overexpression of IRF4 has been well documented in
all these cancers but only a few publications have reported the
association between IRF4 genetic variants or abnormal expression
and skin cancer [29,37–40]. Our results have confirmed the
overexpression of IRF4 in melanoma and supported the claim that
IRF4 may play an important role in the development of this
cancer.
Next, we analyzed the gene expression profiles for IRF4
expression in different types of B cell lymphomas with a total of
336 samples which include 36 cancer cell lines (10.7%), 125
experimentally manipulated B cell lines (37.2%), and 25 normal B
cell samples (7.4%) [41]. As shown in Fig. 1B, amongst the
analyzed lymphoma types, PEL has the highest level of IRF4.
PEL, also known as AIDS-associated body cavity-based lymphoma
(BCBL), is a malignant B cell lymphoma (non-Hodgkin lympho-
ma). PELs are 100% positive for Kaposi sarcoma herpesvirus
(KSHV), and often contain EBV as well. Among 3 types of
DLBCL (Activated, Germinal center, and Type 3), analysis results
from 414 samples reveal that activated DLBCL has the highest
expression level of IRF4 (Fig. 1, C) [42].
In regard to myeloma, analysis results from 304 multiple
myeloma patient samples reveal that there is no significant
difference of IRF4 expression levels among different stages,
including smoldering (Fig. 1, D) [43].
Together, these results indicate that IRF4 is overexpressed in
specific hematological malignancies including myeloma, lympho-
ma, and leukemia, and also in melanoma.
IRF4 Molecular Signatures
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Molecular Signatures Associated with IRF4 in Different
Cancers
Since IRF4 is a ‘‘context-dependent’’ factor, it is necessary to
analyze the patterns of gene expression associated with IRF4 in
individual cancer types.
First, a pool of gene expression profile datasets obtained from
different types of hematological malignancies were analyzed for
genes whose expression is correlated with IRF4 using the
Oncomine website. As to multiple myeloma, the dataset including
124 clinical samples and 7 cell lines (5.3%) was selected for analysis
[44], with default parameters (p value: 1024, fold change: 2, and
gene rank: top 10%). Top 20 genes/probes correlating with IRF4
including ATXN1, HEXB, PSEN2, CASP10, are shown in
Fig. 2A, and top 60 genes are shown in Table S1.
For leukemia, we analyzed the dataset which includes 288 B-
and T-cell acute lymphoblastic leukemia samples [45]. As shown
in Fig. 2B, IRF4 is frequently expressed in B-cell ALL, but not in
T-cell ALL. Top 20 genes/probes correlating with IRF4 include
QRSL1, FAM3C, KIAA0802, WASF1, BLK, ELL3, etc. Top 60
genes are shown in Table S1.
For melanoma, we analyzed the dataset which includes 28
cutaneous melanoma patient samples [46]. Top 20 genes/probes
correlated with IRF4 are shown in Fig. 2C, and top 60 genes/
probes are shown in Table S1. Among these genes, the
transcription factor MITF, the pigmentation enzyme TYR, and
MLANA and GPR143 that are involved in melanosome
biogenesis, are important players in melanoma. MITF is known
to cooperate with IRF4 in regulation of the expression of TYR in
melanocytes [38]. Similar results were obtained from another
dataset (data not shown) [47].
To analyze the molecular signature for IRF4 in cHL, the
dataset including 64 Hodgkin’s lymphoma, 3 T-cell/histiocyte-rich
B-cell lymphoma, 3 Hodgkin’s lymphoma cell lines, and 3
lymphadenitis samples (60 cHL samples in total), was selected
for analysis [48]. As shown in Fig. 2D, overexpression of IRF4 in
cHL is not dependent on EBV infection. Top 20 genes/probes
include SLC26A3, ZNF674, TOX3, FUT9, etc. Top 60 genes/
probes are shown in Table S1.
As to non-Hodgkin’s lymphoma DLBCL, we analyzed a dataset
comprising 414 DLBCL samples [42]. Results indicate that IRF4
Figure 1. Differential expression of IRF4 in different cancer contexts. A. IRF4 is differentially expressed in a panel of cancer cell lines [36]. 1.
Bladder cancer (21 samples); 2. Brain and CNS cancers (64 samples); 3. Breast cancer (56 samples); 4. Colorectal cancer (56 samples); 5. Esophageal
cancer (25 samples); 6. Gastric cancer (35 samples); 7. Head and neck cancer (41 samples); 8. Kidney cancer (21 samples); 9. Leukemia (83 samples); 10.
Liver cancer (29 samples); 11. Lung cancer (166 samples); 12. Lymphoma (61 samples); 13. Melanoma (57 samples); 14. Myeloma (26 samples); 15.
Ovarian cancer (44 samples); 16. Pancreatic cancer (44 samples); 17. Prostate cancer (7 samples). 18. Sarcoma (39 samples). B. Differential expression
of IRF4 in lymphomas [41]. 0. Undesignated (58 samples); 1. Burkitt’s lymphoma (127 samples); 2. Centroblastic lymphoma (28 samples); 3. Chronic
lymphocytic leukemia (34 samples); 4. DLBCL (41 samples); 5. Embryonal rhabdomyosarcoma (1 sample); 6. Follicular lymphoma (6 samples); 7. Hairy
cell leukemia (16 samples); 8. Hodgkin lymphoma (4 samples); 9. Mantle cell lymphoma (8 samples); 10. Multiple myeloma (1 sample); 11. Plasma cell
leukemia (11 samples); 12. Primary effusion lymphoma (9 samples). C. Differential expression of IRF4 in different DLBCLs [42]. 1. Activated B cell-like
DLBCL (167 samples); 2. Germinal center B cell-like DLBCL (183 samples); 3. Type 3 DLBCL (64 samples). D. Differential expression of IRF4 in myeloma
[43]. 1. Monoclonal gammopathy of undetermined significance (2 samples). 2. Multiple myeloma (289 samples); 3. Plasma cell leukemia (3 samples); 4.
Smoldering leukemia (10 samples).
doi:10.1371/journal.pone.0106788.g001
IRF4 Molecular Signatures
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is expressed at a high level in activated DLBCL, along with a panel
of other genes including BATF, LIMD1, CFLAR, PIM2,
CCND2, IL16, miR-155, etc (Fig. 2, E and Table S1). BATF is
an AP1-like transcription factor known to cooperate with IRF4 in
gene transcription in B, T, and dendritic cells [6,8,9,11].
Interestingly, we have previously identified the miR-155-encoding
gene BIC as a target for IRF4 in viral cancer cells [35]. However,
IRF4 is expressed at a lower level in Type 3 DLBCL, and at the
least level in germinal center DLBCL (Fig. 2, E). Similar results
were obtained with another dataset which comprises 271 DLBCL
samples (data not shown) [49].
We also chose the GEO dataset GSE4475 which includes 220
BL and DLBCL samples [50], and performed differential
expression and gene set enrichment analyses, using Limma R
package and MSigDB. Our results show that, similar to other
datasets from Oncomine analysis, BATF, PIM2, LIMD1, CFLAR,
and CCND2, along with a panel of other genes such as STAT3,
CD44, and IL16, are correlated with IRF4. Expression of some
genes such as SSBP2 and MYBL1 is inversely correlated with
IRF4 (Fig. 3). Results with cut-off p value,0.01 and fold change
$2 are shown in Fig. 3 and Table S2. CD44 is known to be
targeted by IRF4 in ABC DLBCL but not in MM [51]. Similar
results were obtained from the GEO datasets GSE4732 which
includes 303 Burkitt’s and B-cell lymphoma samples [52], and
GSE38885 which includes 65 PTLD samples (data not shown).
Taken together, we concluded that IRF4 is associated with
unique molecular signatures in myeloma, leukemia, myeloma,
Hodgkin’s and non-Hodgkin’s lymphomas, and that common
molecular signatures associated with IRF4 in different types of
non-Hodgkin’s lymphomas include BATF, LIMD1, CFLAR,
PIM2, and CCND2, amongst others.
Verification of the Correlation of IRF4 with LIMD1 and
CFLAR in EBV-associated B-cell Lymphoma
The LIMD1 (LIM domain-containing protein 1) gene is located
in a chromosomal region which undergoes frequent loss of
heterozygosity in many solid tumors [53]. Expression of LIMD1 is
absent or decreased in many cancers including breast cancer, lung
carcinoma and blood cancers [53–55]. LIMD1 is an adapter
protein that is involved in the assembly of numerous protein
complexes such as Rb [56] and TRAF6, and participates in several
cellular processes such as repression of gene transcription, cell-cell
adhesion, cell differentiation, proliferation and migration. LIMD1
also positively regulates microRNA (miRNA)-mediated gene
silencing by binding to the core proteins of the microRNA
induced silencing complex (miRISC) such as Ago1/2 [57].
To verify the correlation between IRF4 and LIMD1, a panel of
EBV-negative and -positive B cell lines derived from B lymphomas
or transformed with EBV in vitro were subjected to immunoblot-
ting analysis with IRF4- and LIMD1-specific antibodies. As shown
Figure 2. Molecular signature associated with IRF4 in hemato-
logical malignancies. A. IRF4-associated gene expression pattern in
myeloma. The dataset includes 131 samples [44]. Analysis was
performed with default parameters (p value: 1024, fold change: 2,
and gene rank: top 10%). 0. No value (45 samples); 1. Monoclonal
gammopathy of undetermined significance (5 samples); 2. Multiple
myeloma (81 samples including 74 clinical samples and 7 cell lines). B.
IRF4-associated gene expression pattern in leukemia. The dataset
includes 288 B- and T-cell acute lymphoblastic leukemia samples [45]. 0.
CD10+;CD19+ hematogone (4 samples); 1. B-Cell childhood acute
lymphoblastic leukemia (238 samples); 2. T-cell childhood acute
lymphoblastic leukemia (46 samples). C. IRF4-associated gene expres-
sion pattern in melanoma. The dataset includes 28 cutaneous
melanoma patient samples [46]. D. IRF4-associated gene expression
pattern in classic Hodgkin lymphoma. The dataset includes 64
Hodgkin’s lymphoma, 3 T-cell/histiocyte-rich B-cell lymphoma, 3
Hodgkin’s lymphoma cell lines, and 3 lymphadenitis samples (60 cHL
samples in total) [48]. 0. No value (20 samples); 1. EBV negative (35
samples); 2. EBV positive (18 samples). E. The gene expression pattern
correlated with IRF4 in non-Hodgkin lymphoma DLBCL. The dataset
comprises 414 DLBCL samples [42]. 1. Activated B cell-like DLBCL (167
samples); 2. Germinal center B cell-like DLBCL (183 samples); 3. Type 3
DLBCL (64 samples).
doi:10.1371/journal.pone.0106788.g002
IRF4 Molecular Signatures
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in Fig. 4A, LIMD1 is expressed at high levels in EBV latency 3, in
which both IRF4 and LMP1 are also expressed at high levels.
However, in EBV-negative and type I latency, LIMD1 is not
detectable.
Figure 3. IRF4-associated gene expression pattern in lymphomas. The GEO dataset GSE4475 which includes 220 BL and DLBCL samples [50],
was subjected to bioinformatic analysis for differential gene expression pattern correlated with IRF4 and gene set enrichment, as detailed in Materials
and Methods. The heat map shows results from analysis with cut-off p value,0.01 and fold change$2.
doi:10.1371/journal.pone.0106788.g003
Figure 4. Verification of the correlation of IRF4 with LIMD1 and CFLAR. A. A panel of EBV-negative and -positive B cell lines were subjected
for immunoblotting analysis for IRF4, LIMD1, CFLAR (c-Flip), and LMP1 expression, with specific antibodies. DG75: EBV-negative. Akata and SavI: EBV-
positive with Type I latency. SavIII, P3HR1, and JiJoye were derived from EBV+ Burkitt’s lymphomas. IB4 and LCL.Jul are LCLs established in vitro by
EBV transformation. B. Knockdown of IRF4 in JiJoye cells downregulates the c-Flip protein level in JiJoye cells.
doi:10.1371/journal.pone.0106788.g004
IRF4 Molecular Signatures
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CFLAR encodes c-FLIP, a master inhibitor of Fas/TRAIL/
TNFa-induced apoptosis [58]. Resistance to Fas/TRAIL-mediat-
ed apoptosis is a common mechanism used by tumors to evade the
immune system [59]. Similar to LIMD1, CFLAR expression is
high in type 3 latency, but was not detected in EBV-negative B
cells and EBV type I latency (Fig. 4, A). Furthermore, depletion of
IRF4 in JiJoye cells decreases endogenous CFLAR protein level
(Fig. 4, B). However, depletion of IRF4 did not affect the protein
level of LIMD1 (data not shown), suggesting that LIMD1 and
IRF4 are both upregulated by a common transcription factor
rather than LIMD1 is a direct target for IRF4.
These results confirm that IRF4 is correlated with LIMD1 and
CFLAR in B lymphomas, and strongly suggest that CFLAR is a
transcriptional target for IRF4.
IRF4 Transcriptome in EBV Latency
IRF4 is overexpressed in EBV type 3 latency [17–20]. To our
knowledge, BIC/miR-155 and IRF5 are the only two IRF4 targets
identified in the context of EBV infection [35,60]. To better
understand the role of IRF4 in EBV latency and oncogenesis, we
performed microarray analysis to profile the IRF4 transcriptome
in EBV latency. Endogenous IRF4 expression in JiJoye and IB4
cells was depleted with shIRF4 as described in our previous work
[35]. Knockdown efficiency of IRF4 is shown in Fig. 5, A. Total
RNAs were subjected to microarray analysis. Results show that
434 genes were upregulated (.2.0 fold) and 428 were downreg-
ulated (,2.0 fold) in JiJoye cells stably expressing shIRF4
compared to cells expressing scramble control shRNA, and 324
were upregulated (.2.0 fold) and 198 were downregulated (,2.0
fold) in IB4 cells after IRF4 depletion (Fig. 5, B and Table S3).
Because these two cell lines have different genetic background
(JiJoye is a BL cell line established from a BL patient and IB4 is a
LCL cell line by in vitro transformation of umbilical cord B-
lymphocytes with EBV), only a small portion (about 10%) of
overlapping genes were identified between these two cell lines,
with 54 in the upregulated gene group and 14 in the
downregulated gene group (Fig. 5, B). This observation is
consistent with the fact that IRF4 is a quintessential ‘‘context-
dependent’’ factor which regulates distinct groups of targets in
different contexts [5,16].
Among the overlapping target genes between JiJoye and IB4,
we confirmed the regulation of IFI27, IFI44, IFIT1, GBP1, CD88,
CXCL10, and ARHGAP18 by IRF4 using real-time PCR with
specific primers. IFI27, IFI44, IFIT1, CXCL10 and GBP1 are
known IFN-stimulated genes (ISGs). As shown in Fig. 5C, real-
time PCR results confirmed that IFI27, IFI44 and GBP1
expression levels are significantly elevated after IRF4 depletion,
and ARHGAP18 level is significantly decreased (data for IFIT1,
CD88 and CXCL10 are not shown). IFI27 is a mitochondrial
protein involved in IFN-induced apoptosis [61,62]. IFI44 has anti-
proliferative activity and is known to be associated with HCV
infection [63]. GBP1 acts as a tumor suppressor in colorectal
cancer cells [64], and also plays a role in chronic active EBV
infection and interacts with HCV NS5B [65]. ARHGAP18 a Rho
GTPase-activating protein for RhoA and modulates cell shape,
spreading, and motility [66].
Of note, CFLAR is also downregulated by shIRF4 in JiJoye cells
(1.32 fold) in the microarray results, consistent with the results
from GEO bioinformatics that IRF4 correlates with CFLAR in
non-Hodgkin’s lymphomas and depletion of IRF4 downregulated
CFLAR protein level in EBV+ lymphoma cells (Fig. 4). These data
indicate that CFLAR is also a transcriptional target for IRF4. In
fact, CFLAR is a known target for IRF8 [67], the closest member
to IRF4 in the IRF family.
Figure 5. IRF4 transcriptome in EBV latency. A. Expression of endogenous IRF4 in JiJoye (EBV+ Burkitt’s lymphoma cell line) and IB4 (EBV+ LCL)
cell lines were depleted by retrovirus-mediated transfection of shIRF4 (or control)-expressing retrovirus. Stable transfectants were selected with
hygromycin and shIRF4 (or control) was induced by 1 mg/ml doxycycline. B. Total RNAs were extracted and subjected for Microarray analysis. Genes
with .2.0 and ,2.0 fold changes were selected. C. Real-time PCR confirmation of IRF4 transcriptional targets IFI27, GBP1, IFI44, and ARHGAP18.
doi:10.1371/journal.pone.0106788.g005
IRF4 Molecular Signatures
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106788
Discussion
In this study, we have systematically profiled the molecular
signatures associated with IRF4 expression in a subset of
hematological malignancies including melanoma in which IRF4
is overexpressed. In addition, we have identified a panel of novel
transcriptional targets including IFI27, IFI44, GBP1, CFLAR and
ARHGAP18 for IRF4 in lymphomas.
Gene expression profiling datasets are available online and are
convenient for identification of differential expression of a given
gene and for related high throughput comparison among different
cancers or under different conditions of treatments. Since a large
portion of these datasets were derived from clinical patient
samples, they provide an important resource which complements
in vitro studies. In our analyses, the IRF4-associated molecular
signatures include a subset of IRF4 transcriptional targets such as
CFLAR verified in this study. Other signature genes should be co-
regulated with IRF4 by upstream transcription factors such as
NFkB. In future pursuits, we will combine with other strategies
including cell culture systems to identify IRF4-regulated networks
in individual cancer contexts.
We and others have shown that IRF4 promotes proliferation of
EBV-transformed cells and IRF4 deficiency results in death of cells
derived from different hematological malignancies [17,28,35],
indicating that IRF4 plays a non-redundant role in tumorigenesis
of hematological malignancies. Expression of IRF4 is associated
with resistance to treatment of viral cancers with IFN/AZT, and
AZT specifically induces apoptosis as well as initiates the viral lytic
program in Type I EBV+ Burkitt’s lymphomas [21]. However, the
mechanism of action of IRF4 accounting for this important clinical
observation is unclear. Further study on the interaction between
IRF4 and the IFN-inducible genes including IFI27 and IFI44 may
disclose the mechanism through which IRF4 confers resistance to
IFN treatment of vial cancers by regulating their expression.
Consistent with our finding that CFLAR is a transcriptional
target for IRF4, CFLAR has been shown to be targeted by IRF8,
the closest family member of IRF4 [67]. Correspondingly, we have
identified a potential IRF4/8-binding site EICE in the CFLAR
gene promoter (not shown). We will verify if this EICE is
functional and responsible for IRF4/8 regulation. Targeting
CFLAR by IRF4 may implicate a role for IRF4 in Fas/TRAIL/
TNFa-induced apoptosis in non-Hodgkin lymphomas.
The implication of IRF4 in hematological malignancies is
increasingly recognized. However, most evidence has emerged
from clinical observations. Recent efforts have focused on the
identification of ‘‘context-dependent’’ co-factors for IRF4 [2–11].
To date, only limited targets including miR-155 [35], IRF5 [60],
Blimp1, CCNB1, BCL6, CDK6, Myc, and several others have
been identified as IRF4 targets in cancers [7,25,28,68]. Clearly,
identification of IRF4-specific gene regulation networks will
improve our understanding of its functional roles in distinct
cancer contexts. Our following work will aim to disclose the roles
of the novel IRF4 targets identified in our study in EBV
oncogenesis.
In addition to the downstream gene regulatory networks, our
recent observation that IRF4 is activated through Src-mediated
tyrosine phosphorylation in EBV-associated lymphomas [69],
represents another important topic and a novel challenge for
studying the interaction of IRF4 with hematological malignancies.
We are encouraged to identify lymphocyte-specific signaling
pathways leading to IRF4 activation, which potentially opens
new avenues for targeting IRF4 networks for future clinical
treatments.
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